Of all the reasons people buy alpha-lipoic acid, nerve pain in the feet is the one with the most human evidence behind it, and also the one where the fine print matters most.
Quick answer: Alpha-lipoic acid (ALA) has been tested for diabetic peripheral neuropathy symptoms in several randomized trials and meta-analyses. Intravenous ALA at 600 mg daily for about three weeks produced consistent short-term improvement in symptom scores; oral ALA at 600 mg daily showed smaller, less consistent benefit over weeks to months. It did not reverse nerve damage, and the longest trial did not show a change in how neuropathy progressed over four years.
Why neuropathy is where the ALA research is concentrated
Diabetic peripheral neuropathy is nerve damage that typically starts in the toes and feet and moves upward. It causes burning, tingling, stabbing pain, numbness, or a combination. It affects a large share of people who have had diabetes for many years and is one of the complications that most affects daily life.
Standard treatments for the pain (certain antidepressants, anticonvulsants, topical agents) help some people and carry side effects of their own. That gap, plus a plausible mechanism (oxidative stress is believed to contribute to nerve damage in high-glucose conditions), is why ALA attracted research funding in Germany starting decades ago. In Germany it is licensed as a prescription drug for this purpose. In the United States it is sold as a supplement. The supplements for metabolic syndrome hub explains how it fits among other options; this article is only about the nerve question.
What the trials actually found
The research falls into two groups that are often blurred together on product pages.
Intravenous trials. The best-known studies gave 600 mg of ALA by IV infusion daily for about three weeks. Pooled analyses of these trials, totaling a little over a thousand participants, found a consistent improvement in a standardized symptom score (the Total Symptom Score, which rates pain, burning, tingling, and numbness) compared with placebo. The effect size was moderate and considered clinically meaningful by the researchers. These trials were short, and the benefit was measured at the end of the three weeks, not months later.
Oral trials. Oral ALA is what you can buy. A five-week trial compared 600, 1,200, and 1,800 mg per day by mouth with placebo in around 180 participants. All three doses improved symptom scores more than placebo, and 600 mg had the fewest side effects, which is where the “600 mg” figure you see everywhere comes from. Several smaller oral trials since then have pointed in the same direction, with more variability.
The long trial. One four-year trial gave 600 mg oral ALA daily to roughly 460 people with mild to moderate neuropathy. The primary outcome, a combined measure of symptoms and nerve function, did not differ between ALA and placebo. Some secondary measures favored ALA, and the placebo group’s neuropathy progressed less than researchers expected, which made it hard to detect a difference. Supplement sellers rarely mention this trial. A PubMed search on ALA and diabetic neuropathy will surface it along with the others.
What the research does not show
It does not show that ALA repairs nerves or restores sensation that is already gone. Symptom scores improved; objective nerve conduction measures changed little or not at all in most studies. It does not show that oral ALA matches the IV results. It does not show long-term benefit beyond a few months, and the one trial that tried to show it did not. And it does not show anything about preventing neuropathy in people who have prediabetes or early type 2 and no symptoms yet; those people were not studied for this outcome.
That last point matters for readers of this site. If you were recently diagnosed and are reading the prediabetes guide or the insulin resistance guide, the neuropathy evidence is about a different population than you.
Doses as studied
The oral dose used in most positive trials was 600 mg once daily, usually taken before breakfast on an empty stomach because food reduces absorption. Higher doses (1,200 and 1,800 mg) were tested and caused more nausea without clearly more benefit. Whether 600 mg or any amount is right for you is a decision for the clinician managing your neuropathy, not a number to copy from an article. The dosage and timing article covers how the trials handled timing and divided doses.
The IV protocols are a medical procedure, not something available at a supplement store, and the oral form should not be assumed to replicate them.
Reading the label for a neuropathy purchase
Nearly all neuropathy trials used racemic ALA (the 50/50 R and S mixture). Products advertising “R-ALA” or “stabilized R-ALA” as superior for nerve symptoms are extrapolating from absorption data, not neuropathy trials. R-ALA vs. regular alpha-lipoic acid covers that debate. Check the per-day total rather than per-capsule milligrams, and look for independent third-party testing. Metabolic Clarity Labs sells berberine, not ALA; hold any product, MCL’s included, to the same testing standard.
Safety, side effects, and medication interactions
At 600 mg daily, side effects in trials were mainly nausea and stomach upset, rising with higher doses. Skin rash and an unusual body odor have been reported. A rare autoimmune reaction, insulin autoimmune syndrome, can cause severe unpredictable hypoglycemia and has been linked to ALA mainly in people with a specific genetic variant more common in East Asian populations. ALA side effects and interactions goes deeper.
Hypoglycemia warning: Combining any blood-sugar-active supplement with insulin, sulfonylureas, or other glucose-lowering medicines can push glucose too low. Symptoms include shakiness, sweating, confusion, and a fast heartbeat. Do not add a supplement to a medication plan without your prescriber’s knowledge.
Concrete interactions: ALA can add to the glucose-lowering effect of insulin and oral diabetes medicines, which matters because most people with neuropathy are on one or more of them. It may interfere with thyroid hormone and is typically separated from levothyroxine by several hours. Because it acts as an antioxidant, oncologists usually ask patients to stop it during chemotherapy or radiation. Alcohol and thiamine deficiency are a concern: ALA plus heavy alcohol use has been associated with worsened thiamine problems in case reports. The NCCIH page on diabetes and dietary supplements summarizes the safety picture. The ALA and blood sugar article covers the glucose evidence separately, since it is a different body of research.
Questions to bring to your appointment
- Has my neuropathy been formally assessed (monofilament test, vibration, nerve conduction), so we have a baseline to compare against?
- Is my current glucose control the first thing to address, since that is the strongest known lever on neuropathy progression?
- Given the medicines I take for pain and for diabetes, is there a specific reason ALA would be a problem?
- If I tried 600 mg daily for eight to twelve weeks, how would we decide whether it helped, and what symptom change would be worth continuing for?
- Should I expect it to do anything for numbness, or mainly for burning and tingling?
- Have I had vitamin B12 checked recently, especially if I take metformin, since B12 deficiency can mimic or worsen neuropathy?
The neuropathy evidence for ALA is real, limited, and mostly about symptoms over weeks rather than nerves over years. Knowing that distinction before you buy is the whole point of reading the studies instead of the label.
About the author: Charles Kirkland is the founder of Metabolic Clarity Labs and author of The Journey Back. He is not a physician. This is general education, not a medically reviewed treatment plan.
Sources checked October 29, 2026. Discuss personal decisions with a qualified clinician or pharmacist. Do not start, stop, or change prescribed treatment based on this article.
Leave a Reply